P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study. (April 2023) - Kümmel, S.; Schmid, P.; Harbeck, N.; Takahashi, M.; Untch, M.; Boileau, J.-F.; Cortes, J.; McArthur, H.; Dent, R.; O'Shaughnessy, J.; Pusztai, L.; Foukakis, T.; et al.